Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jun 6;30(7):1913–1922. doi: 10.1038/s41591-024-03044-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a, OS of 384 patients with high-risk cancers. b, Number of PGT recommendations per patient. c, Frequency of PGT recommendations according to cancer type. d, Number of PGT recommendations from the highest level of supporting evidence to the lowest (tier 1, clinical evidence in the same cancer; tier 2, clinical evidence in a different cancer; tier 3, preclinical evidence in the same cancer; tier 4, preclinical evidence in a different cancer; tier 5, consensus opinion). e, Distribution of PGT recommendation tier according to cancer type. f, Types of targeted therapy in relation to the drug target. Targeted therapy was categorized into targeted monotherapy, targeted dual therapy and targeted agent in combination with chemotherapy. The corresponding molecular pathway for each of the drug targets is shown. c, P values for comparison of proportions using a two-sided chi-squared test.